Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03213145 | Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers | PHASE1 | COMPLETED | 48 | — | — | Jul 11, 2017 | Sep 7, 2017 | Nov 6, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| intraconazole | DRUG | Subjects will receive itraconazole once daily from Day 5 through Day18 |
| Rifampin | DRUG | Subjects will receive rifampin once daily from Day 5 through Day 16 |
| EDP 305 | DRUG | Subjects will receive EDP 305 once daily on Day 1 and Day 14 |
Inclusion Criteria: * An informed consent document signed and dated by the subject. * Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive. * Female subjects must be of non-childbearing potential. Exclusion Criteria: * Clinically relevant evidence o...